NCT07708597Active, not recruiting
Effects of Neuromuscular Electrical Stimulation Combined With Ultrasound on Stroke Patients With Sarcopenia
A Randomized Controlled Trial of Neuromuscular Electrical Stimulation Combined With Therapeutic Ultrasound on Muscle Mass, Muscle Strength, and Physical Function in Stroke Patients With Sarcopenia.
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if combining neuromuscular electrical stimulation (NMES) with therapeutic ultrasound (UT) can improve muscle mass, muscle strength, and physical function in stroke patients with sarcopenia. The main questions it aims to answer are: Does combined NMES and UT therapy increase muscle mass and strength more than conventional rehabilitation alone? Does the combined therapy improve physical function (balance, gait, and activities of daily living) better than either therapy alone? Researchers will compare four groups: Conventional rehabilitation only (control group) Conventional rehabilitation plus UT Conventional rehabilitation plus NMES Conventional rehabilitation plus combined UT and NMES Participants will: Receive 4 weeks of rehabilitation therapy, 6 days per week Undergo assessments of muscle mass (via ultrasound), muscle strength (handgrip, isokinetic testing), and physical function (Fugl-Meyer, FIM, balance, and gait tests) before and after the 4-week intervention Receive either UT (1 MHz, 0.5-0.8 W/cm², 20 min/session, 2 sessions/day), NMES (50 Hz, 300μs pulse width, 20 min/session, 2 sessions/day), both, or standard care only
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 152 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 1 May 2025
- Primary completion date
- 1 Nov 2025
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
- Diseases
- Stroke
- NCT number
- NCT07708597
What you commit to
- Study type: Interventional
- Planned participants: 152
- From 1 May 2025 to the primary completion date, 1 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of significant emotional or cognitive impairment.
- Obesity or overweight (body mass index \> 25 kg/m²).
- Unable to stand up from a chair with or without assistance.
- Comorbidities including renal, hepatic, or heart failure.
Who the study is looking for
- Diagnosis of first-ever stroke confirmed by CT or MRI, with stable vital signs, disease course between 3 weeks and 6 months.
- Diagnosis of sarcopenia according to the 2019 Asian Working Group for Sarcopenia (AWGS) criteria: reduced handgrip strength (male \< 28 kg, female \< 18 kg) and/or gait speed \< 1.0 m/s, and reduced appendicular skeletal muscle mass index (male \< 7.0 kg/m², female \< 5.4 kg/m²).
- Age between 30 and 75 years.
- Brunnstrom stage of affected upper and lower limbs ≥ III, and modified Ashworth scale ≤ 2.
- No significant consciousness or cognitive impairment.
- Willing and able to provide written informed consent.
Age in the registry: 30 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing First Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.